Sigachi Industries Achieves Key R&D Milestone in Cystic Fibrosis APIs, Eyes Annual Revenue Potential of ~X250 Crore

Sigachi Industries Ltd., a leading Indian pharmaceutical company, has announced a significant milestone in its research and development pipeline with the successful advancement of a new Cystic Fibrosis (CF) Active Pharmaceutical Ingredients (APIs) combination comprising Vanzacaftor, Tezacaftor, and Deutivacaftor. This development marks an important step in Sigachi’s strategic focus on expanding its presence in complex, high-value specialty APIs, aligned with global demand for advanced therapies in rare and chronic disease segments. The global cystic fibrosis therapeutics market is estimated to exceed USD 10 billion, and Sigachi’s entry into CF APIs positions the Company in a structurally strong and innovation-led therapeutic segment with long-term demand visibility. Subject to successful partnerships and market progression, the Company estimates a revenue potential of approximately X250 crore per annum commencing from Q4 FY2026-27.